Market revenue in 2023 | USD 100.8 million |
Market revenue in 2030 | USD 248.1 million |
Growth rate | 13.7% (CAGR from 2023 to 2030) |
Largest segment | Epinephrine |
Fastest growing segment | Immunotherapies |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Antihistamines, Epinephrine, Immunotherapies, Other Drug Class |
Key market players worldwide | Nestle SA, Sanofi SA, DBV Technologies SA ADR, PureTech Health PLC, Regeneron Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd ADR, Protagonist Therapeutics Inc, Aravax, Alladapt Immunotherapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to peanut allergy treatment market will help companies and investors design strategic landscapes.
Epinephrine was the largest segment with a revenue share of 48.12% in 2023. Horizon Databook has segmented the Asia Pacific peanut allergy treatment market based on antihistamines, epinephrine, immunotherapies, other drug class covering the revenue growth of each sub-segment from 2018 to 2030.
Across the Asia Pacific region, the peanut allergy treatment market exhibits notable variations. Some countries, such as Australia, face a relatively high prevalence of peanut allergies and others, such as China, show lower incidence rates. Understanding these regional disparities is crucial for market stakeholders. It is essential to recognize the diverse trends and adapt strategies accordingly.
In certain countries like Japan, advancements in medical research are contributing to potential treatments, but they may face unique challenges. For example, the termination of a promising DNA vaccine project by Astellas Pharma, Inc. in Japan highlights the complexities and risks involved in developing peanut allergy treatments.
Moreover, Traditional Chinese Medicine (TCM) is gaining attention due to its potential to address allergies, including peanut allergies. The long-standing reputation of TCM for effectiveness, costefficiency, & safety is attracting interest in China and Western societies. However, there is a need to carefully consider how TCM may impact the broader modern medicine market.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific peanut allergy treatment market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific peanut allergy treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account